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The Global Burden of Disease study re-
vealed that both cirrhosis and liver cancer
were among the top 20 causes for mortal-
ity, but when these 2 forms of end-stage
liver disease are taken together, liver dis-
ease moves into the top 10, with levels of
mortality and morbidity similar to those
exerted by human immunodeﬁciency
virus (HIV) infection, tuberculosis, and
malaria [1, 2]. On a global scale, the ma-
jority of liver-related mortality is attribut-
able to viral hepatitis due to chronic
hepatitis C virus (HCV) and chronic hep-
atitis B virus (HBV) infections. According
to recent estimates from the World Health
Organization, 170 million people world-
wide are chronically infected with HCV
[3]. However, the distribution of infection
is heterogeneous, with the majority of in-
fected people living in low-income or
low-middle-income countries (LMICs).
Over the last 5 years, we have witnessed
a therapeutic transformation for HCV
infection, wherein treatment efﬁcacy,
tolerability, and durations have all sub-
stantially improved. The mainstay of
treatment for the last 20 years has been
pegylated interferon and ribavirin, which
delivered a 50% chance of cure after 48
weeks of treatment, accompanied by my-
riad side effects. In contrast, >95% of non-
cirrhotic patients with HCV genotype 1
infection (including those coinfected
with HIV) can now reasonably expect
cure after a 12-week regimen, without
any side effects, mostly with interferon-
and ribavirin-free combinations [4, 5].
However, access to the new all-oral antivi-
ral treatment regimens is limited, and the
cost of the drugs is not the only barrier.
Despite the high prevalence and bur-
den of disease, there are very few pro-
grams or facilities in resource-limited
settings to screen and manage viral hepa-
titis infections [6]. Management of hepati-
tis C requires access to virologic diagnostic
assays, tools to assess disease stage, and
skilled physicians to coordinate care and
effective drugs. Virology laboratories in
LMICs are rare and frequently are central-
ized. Although many laboratories have the
facilities to perform molecular diagnostic
assays, including real-time polymerase
chain reaction assays, the cost of the
tests, invariably borne directly by the pa-
tient, are substantially higher than costs
in Europe and North America. An addi-
tional barrier to access viral diagnostic
tests is that, for collection of blood speci-
mens, patients must travel to a clinic
close to the laboratory, because of lack of
phlebotomy facilities and logistical issues
with sample transportation.
A practical solution to the problem of
blood sample collection and transport is
the use of capillary samples collected on
ﬁlter paper as dried blood spots (DBS).
Until now, however, uncertainty has per-
sisted over the sensitivity and speciﬁcity
of diagnostic tests of DBS for HCV. The
article by Soulier et al in this issue of
The Journal of Infectious Diseases directly
and positively addresses this issue [7].
Using parallel venous blood samples col-
lected conventionally and as DBS, Soulier
et al demonstrated high sensitivity and
speciﬁcity for anti-HCV antibody tests
and for HCV load tests, using both the
Abbott m2000 platform and the Roche
Cobas Ampliprep/Cobas TaqMan HCV
system, version 2. However, the sensitiv-
ity of HCV core antigen detection on
DBS was unacceptably low, which is
disappointing because the assay is per-
formed on the ubiquitous Architect plat-
form and is approximately 30% cheaper
than real-time PCR for the detection of
viremia [8]. As point-of-care tests are
being developed that focus on HCV core
antigen quantiﬁcation as a surrogate
marker of HCV replication in LMICs, it
is essential to perform more research on
the use of DBS for this speciﬁc diagnostic
test. Extraction of HCV RNA from DBS
appears to be effective, using methods
that would readily transfer to laboratory
facilities in LMICs.
DBS sampling has been widely used in
sub-Saharan Africa for diagnosing infec-
tious diseases, monitoring HIV infection,
and for epidemiological surveillance.
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Previous studies of anti-HCV antibody
serologic assays of DBS have shown good
sensitivity and speciﬁcity, but there are
very few data on testing for viremia.
Tuaillon et al compared DBS to venous
samples for measurement of HCV vire-
mia, using the Cobas Taqman assay, and
found a good correlation of viral loads,
but the absolute values were an average
of 2.27 log IU/mL lower in DBS [9]. In
the current study, viral loads were 1.60–
1.75 log IU/mL lower in DBS.
Inevitably, the sensitivity of viral load
detection and measurement at the lower
end of the dynamic range (ie, <1.75 log
IU/mL) for DBS will not be as good as
that for conventional plasma or serum
samples. This should not signiﬁcantly
compromise the use of DBS-based testing
in untreated patients: because viral loads
in such individuals are typically higher
than levels in treated patients, the sensi-
tivity is not affected. The lack of sensitiv-
ity at lower levels of viremia may limit the
use of DBS for monitoring during treat-
ment, which has been an important com-
ponent of HCV therapy in the interferon
era, but is unlikely to be as important in
the new era of direct-acting antivirals,
during which dynamic monitoring of
viral load has no proven beneﬁt [10].
Indeed, the few patients who experience
virological relapse during or after direct-
acting antiviral–based treatment do so
with high viral loads, well above the limit
of detection in DBS. Therefore, the evalu-
ation of virological success rates should not
be hampered by the detection threshold.
To surmount the logistical barriers
found in LMICs, it is essential that DBS
remain stable at room temperature. In
the study by Soulier et al, viral loads in
DBS stored at room temperature for 19
months remained virtually identical to
those in DBS stored at −80°C. In contrast,
Tuaillon et al found that viral loads in
DBS deteriorated after specimens were
stored for 7 days at room temperature
[9]. The stability of viral loads in DBS
stored at room temperature is a vital char-
acteristic for deployment of DBS testing
in the ﬁeld and needs to be conﬁrmed
in light of these inconsistent ﬁndings.
Of note, the value of DBS testing for
HCV extends beyond LMICs. Because
the routes of transmission of HCV in de-
veloped countries include injection drug
use and, among men who have sex with
men, violent anal sex, the use of DBS may
become an invaluable tool for HCV test-
ing in treatment centers for illicit drug
[11] and alcohol use, in sexual health
clinics, and in prisons, where the risk of
acute infection and the prevalence of
chronic infection are high. In these envi-
ronments, access to phlebotomy and fre-
quent problems with venous access make
it difﬁcult to rely on conventional venous
blood testing, and recent publications in-
dicate that the uptake of HCV testing
has been increased by the use of DBS.
Although DBS were useful for estimat-
ing viral load, viral genotyping could only
be achieved for 84.5% of samples in the
study by Soulier et al study, and it would
be reasonable to expect lower rates of suc-
cessful genotyping in the real world. Does
this matter? Probably not. Currently,
sofosbuvir-based regimens can be con-
sidered to have pangenotypic coverage,
albeit with slightly less efﬁcacy against
HCV genotype 3. Admittedly, the Abbvie
regimen (ombitasvir/paritaprevir/ritona-
vir and dasabuvir) is only effective against
HCV genotypes 1 and 4. Nevertheless, fu-
ture all-oral regimens are expected to be
pangenotypic, making the requirement
for genotype testing obsolete.
With limited reservations, DBS collec-
tion provides a solution to one of the
practical barriers to HCV treatment ac-
cess in LMICs. Simpliﬁcation of drug
regimens and pangenotypic antiviral
drugs should reduce the level of clinical
expertise required to deploy therapy. Ge-
neric pricing agreements for HCV drugs
are already being negotiated. Perhaps it is
time for optimism around access to HCV
treatment.
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